Here at Atomwise, we are really proud of the AtomNet® tool we’ve built to perform virtual screening of targets against billions of compounds to find promising candidates. This approach has already provided new leads for academic labs and drug […]
You probably hear about AI on a regular basis, but if you’re not a programmer steeped in machine learning algorithms, AI can seem like a mysterious black box.
Drug discovery startup Atomwise, which joined the NVIDIA Inception virtual accelerator program in 2018, developed AtomNet, a convolutional neural network for small molecule drug discovery. The AtomNet AI technology can screen more than 16 billion […]
"Atomwise is a member of NVIDIA Inception, a program that supports AI startups with go-to-market support, expertise, and technology. Atomwise developed the AtomNet® model, the first convolutional neural network (CNN) for drug discovery, capable of […]
At the American Chemical Society Fall 2020 Virtual Meeting & Expo, several Atomwise members and partners were selected to present their research and work. Learn what our Atoms have been working on below and visit Atomwise at ACS Fall 2020 Virtual […]
- by Abraham Heifets, co-founder and CEO of Atomwise originally posted on Medium In their cogent and insightful discussion about the different perspectives of Tech and Biotech investors, Drs. Shaywitz and Gibson make the implicit assumption that AI […]
- by Stefan Schroedl, Head of Machine Learning at Atomwise Originally posted on Medium This post is intended for my fellow machine learning engineers who are curious about applications in medicine, biology, or chemistry, but without a prior formal […]
- by Stefan Schroedl, Head of Machine Learning at Atomwise Originally posted on Medium Introduction Having applied machine learning to search and advertising for many years, two years ago I was ready for a transition to something new. In particular, […]
To understand Atomwise, it helps to know a little about how drug discovery works.